AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Illumina on 6/30 was $176.07 Million, Ranking 580
ByAinvest
Monday, Jun 30, 2025 6:00 pm ET1min read
The turnover of Illumina on 6/30/2025 was $176.07 million, ranking 580 in today's market, the Volume is 1.85 million.
Illumina(ILMN) shares closed at $95.41, up 0.65% on 6/30/2025, up 5.30% in the last 5 trading days, up 16.01% this month, down 28.60% year-to-date and down 9.56% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 6/30/2025 | $176.07 million | 1.85 million | $95.41 | 0.65% |
| 6/27/2025 | $363.39 million | 3.84 million | $94.79 | 0.67% |
| 6/26/2025 | $276.10 million | 2.93 million | $94.16 | 1.00% |
| 6/25/2025 | $342.79 million | 3.69 million | $93.23 | 1.87% |
| 6/24/2025 | $211.62 million | 2.32 million | $91.52 | 1.00% |
【Company Profile】
Illumina, Inc. is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. The company was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. Using its proprietary technologies, the company provide a comprehensive line of genetic analysis solutions, with products and services that serve a broad range of highly interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The company's customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet